Niloofar Rahmani

Array ( [id] => 19165787 [patent_doc_number] => 11981673 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-05-14 [patent_title] => 7-isopropyl 1,2-dimethyl 3-(substituted benzoyl)indolizine-1,2,7 tricarboxylates as adenosine receptor active compounds [patent_app_type] => utility [patent_app_number] => 18/377348 [patent_app_country] => US [patent_app_date] => 2023-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7725 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18377348 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19800456 [patent_doc_number] => 20250066381 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => ONE-POT, MULTI-COMPONENT MANUFACTURING METHOD FOR TETRAHYDROTHIENOPYRIDINE DERIVATIVES INCLUDING N-SUBSTITUTED AMINO ACIDS [patent_app_type] => utility [patent_app_number] => 18/481808 [patent_app_country] => US [patent_app_date] => 2023-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5820 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18481808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19202769 [patent_doc_number] => 20240174668 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 [patent_app_type] => utility [patent_app_number] => 18/480925 [patent_app_country] => US [patent_app_date] => 2023-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40780 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18480925 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19248619 [patent_doc_number] => 20240199606 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 [patent_app_type] => utility [patent_app_number] => 18/480164 [patent_app_country] => US [patent_app_date] => 2023-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41060 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18480164 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19248618 [patent_doc_number] => 20240199605 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE [patent_app_type] => utility [patent_app_number] => 18/475499 [patent_app_country] => US [patent_app_date] => 2023-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 101913 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18475499 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19730155 [patent_doc_number] => 12208141 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-28 [patent_title] => Anti-cancer nuclear hormone receptor-targeting compounds [patent_app_type] => utility [patent_app_number] => 18/472993 [patent_app_country] => US [patent_app_date] => 2023-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35950 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18472993 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20315990 [patent_doc_number] => 12454532 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-28 [patent_title] => Inhibiting cyclic AMP-responsive element-binding protein (CREB) binding protein (CBP) [patent_app_type] => utility [patent_app_number] => 18/371647 [patent_app_country] => US [patent_app_date] => 2023-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 10 [patent_no_of_words] => 9102 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18371647 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19216195 [patent_doc_number] => 20240180899 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => BENZAMIDE COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/471017 [patent_app_country] => US [patent_app_date] => 2023-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43069 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18471017 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19140420 [patent_doc_number] => 20240139203 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-02 [patent_title] => USE OF EZH2 INHIBITORS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/462229 [patent_app_country] => US [patent_app_date] => 2023-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30338 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18462229 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19003577 [patent_doc_number] => 20240067648 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => N-OXIDE INHIBITORS OF NLRP3 INFLAMMASOME [patent_app_type] => utility [patent_app_number] => 18/462015 [patent_app_country] => US [patent_app_date] => 2023-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19756 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18462015 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18844448 [patent_doc_number] => 20230406852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/240805 [patent_app_country] => US [patent_app_date] => 2023-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60649 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18240805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19157641 [patent_doc_number] => 20240150348 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => BRD9 DEGRADERS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/456301 [patent_app_country] => US [patent_app_date] => 2023-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37354 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 274 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18456301 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19012985 [patent_doc_number] => 11919900 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-03-05 [patent_title] => 1-substituted benzoyl-4-bromopyrrolo[1,2-a]quinoline-3-carboxylate derivatives as antitubercular agents [patent_app_type] => utility [patent_app_number] => 18/236237 [patent_app_country] => US [patent_app_date] => 2023-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7332 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18236237 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19809475 [patent_doc_number] => 12240846 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-04 [patent_title] => 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases [patent_app_type] => utility [patent_app_number] => 18/233259 [patent_app_country] => US [patent_app_date] => 2023-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 94147 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18233259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20115991 [patent_doc_number] => 12365680 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-22 [patent_title] => Polymorphs of the hydrochloride salt of linaprazan glurate [patent_app_type] => utility [patent_app_number] => 18/232033 [patent_app_country] => US [patent_app_date] => 2023-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 4984 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18232033 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19003539 [patent_doc_number] => 20240067610 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => INHIBITORS OF NLRP3 INFLAMMASOME [patent_app_type] => utility [patent_app_number] => 18/353422 [patent_app_country] => US [patent_app_date] => 2023-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47724 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18353422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19491594 [patent_doc_number] => 12110290 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-08 [patent_title] => Triazolopyridinyl compounds as kinase inhibitors [patent_app_type] => utility [patent_app_number] => 18/347703 [patent_app_country] => US [patent_app_date] => 2023-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 98867 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18347703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20671901 [patent_doc_number] => 12612401 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-28 [patent_title] => Crystalline forms of an S1P receptor modulator [patent_app_type] => utility [patent_app_number] => 18/347491 [patent_app_country] => US [patent_app_date] => 2023-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 18 [patent_no_of_words] => 17593 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18347491 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19003571 [patent_doc_number] => 20240067642 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => COMPOUNDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/216280 [patent_app_country] => US [patent_app_date] => 2023-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 77232 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18216280 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19737162 [patent_doc_number] => 12213969 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-04 [patent_title] => 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors [patent_app_type] => utility [patent_app_number] => 18/215887 [patent_app_country] => US [patent_app_date] => 2023-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54112 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 454 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18215887 [rel_patent_id] =>[rel_patent_doc_number] =>)